<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27854206</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2214-3599</ISSN><JournalIssue CitedMedium="Print"><Volume>3</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of neuromuscular diseases</Title><ISOAbbreviation>J Neuromuscul Dis</ISOAbbreviation></Journal><ArticleTitle>Sexual Reassignment Fails to Prevent Kennedy's Disease.</ArticleTitle><Pagination><StartPage>121</StartPage><EndPage>125</EndPage><MedlinePgn>121-125</MedlinePgn></Pagination><Abstract><AbstractText>Spinal and bulbar muscular atrophy is caused by polyglutamine expansion in the androgen receptor. As an X-linked disease dependent on androgens, symptoms and findings are only fully manifest in males. Here we describe a 40-year-old male-to-female transgender SBMA patient who developed full disease manifestations despite undetectable levels of androgens. We used cell culture and animal models to show that spironolactone, the anti-androgen she had taken for 15 years, promotes nuclear localization and toxicity of the mutant protein, which may explain the disease manifestations in this patient.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanman</LastName><ForeName>Tyler A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakar</LastName><ForeName>Dara</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badders</LastName><ForeName>Nisha M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Ailbhe</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kokkinis</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shrader</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Clinical Center, Department of Health and Human Services, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joe</LastName><ForeName>Galen O</ForeName><Initials>GO</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Clinical Center, Department of Health and Human Services, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schindler</LastName><ForeName>Alice B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bott</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harmison</LastName><ForeName>George G</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>J Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Howard Hughes Medical Institute, Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischbeck</LastName><ForeName>Kenneth H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunseich</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 CL999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neuromuscul Dis</MedlineTA><NlmUniqueID>101649948</NlmUniqueID></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000726">Androgen Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>27O7W4T232</RegistryNumber><NameOfSubstance UI="D013148">Spironolactone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000726" MajorTopicYN="N">Androgen Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004330" MajorTopicYN="N">Drosophila</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057829" MajorTopicYN="N">Sex Reassignment Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013148" MajorTopicYN="N">Spironolactone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014189" MajorTopicYN="N">Transsexualism</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Motor neuron disease</Keyword><Keyword MajorTopicYN="N">X-Linked</Keyword><Keyword MajorTopicYN="N">androgen</Keyword><Keyword MajorTopicYN="N">bulbo-spinal atrophy</Keyword><Keyword MajorTopicYN="N">receptors</Keyword><Keyword MajorTopicYN="N">spironolactone</Keyword></KeywordList><CoiStatement>CONFLICT OF INTEREST. The authors have no conflict of interest to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27854206</ArticleId><ArticleId IdType="mid">NIHMS1923252</ArticleId><ArticleId IdType="pmc">PMC10427994</ArticleId><ArticleId IdType="doi">10.3233/JND-150128</ArticleId><ArticleId IdType="pii">JND150128</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grunseich C, Rinaldi C, Fischbeck KH. Spinal and bulbar muscular atrophy: Pathogenesis and clinical management. Oral Diseases. 2013;20(1):6&#x2013;9. doi: 10.1111/odi.12121</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/odi.12121</ArticleId><ArticleId IdType="pmc">PMC4284073</ArticleId><ArticleId IdType="pubmed">23656576</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuno M, Adachi H, Kume A, Li M, Nakagomi Y, Niwa H, et al. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron. 2002;35(5):843&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">12372280</ArticleId></ArticleIdList></Reference><Reference><Citation>Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: Mechanism of action. Endocrinology. 1975;97(1):52&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">166833</ArticleId></ArticleIdList></Reference><Reference><Citation>Gardiner P, Schrode K, Quinlan D, Martin BK, Bore-ham DR, Rogers MS, et al. Spironolactone metabolism: Steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29(4):342&#x2013;347.</Citation><ArticleIdList><ArticleId IdType="pubmed">2723123</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim A Spironolactone: Disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab Rev. 1978; 8(1):151&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">363379</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelsky NB, Pennuto M, Smith RB, Palazzolo I, Moore J, Nie Z, et al. Native functions of the androgen receptor are essential to pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron. 2010;67(6):936&#x2013;952. doi: 10.1016/j.neuron.2010.08.034</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2010.08.034</ArticleId><ArticleId IdType="pmc">PMC3514079</ArticleId><ArticleId IdType="pubmed">20869592</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris-Love MO, Fernandez-Rhodes L, Joe G, Shrader JA, Kokkinis A, La Pean Kirschner A, et al. Assessing function and endurance in adults with spinal and bulbar muscular atrophy: Validity of the adult myopathy assessment tool. Rehabil Res Pract. 2014;2014:1&#x2013;16. doi: 10.1155/2014/873872</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/873872</ArticleId><ArticleId IdType="pmc">PMC4026974</ArticleId><ArticleId IdType="pubmed">24876969</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundar S, Dickinson PD. Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Rep. 2012. doi: 10.1136/bcr.11.2011.5238</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr.11.2011.5238</ArticleId><ArticleId IdType="pmc">PMC3291010</ArticleId><ArticleId IdType="pubmed">22665559</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xe9;rouanne B, Tahiri B, Georget V, Belon C, Poujol N, Avances C, et al. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Mol Cell Endocrinol. 2000;160(1&#x2013;2):39&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10715537</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhodes LE, Freeman BK, Auh S, Kokkinis AD, La Pean A, Chen C, et al. Clinical features of spinal and bulbar muscular atrophy. Brain. 2009;132:3242&#x2013;51. doi: 10.1093/brain/awp258</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awp258</ArticleId><ArticleId IdType="pmc">PMC2792370</ArticleId><ArticleId IdType="pubmed">19846582</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>